Italian results of the PRECONNECT study: safety and efficacy of trifluridine/tipiracil in metastatic colorectal cancer.


Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Jun 2021
Historique:
pubmed: 6 3 2021
medline: 30 11 2021
entrez: 5 3 2021
Statut: ppublish

Résumé

The international PRECONNECT Phase IIIb study demonstrated safety and efficacy of trifluridine/tipiracil in the management of patients with metastatic colorectal cancer. Lay abstract PRECONNECT is an international study demonstrating the efficacy and tolerability of the drug combination trifluridine/tipiracil in adult patients with metastatic colorectal cancer treated in everyday clinical practice. For this publication, the authors conducted an analysis performed on the 161 Italian patients enrolled in this study. These kinds of analyses are important because of the differences that may arise across different countries. The most common contraindications were not dangerous to health. Furthermore, 3 months from beginning the medication, half of the patients did not show a worsening of the disease and quality of life during treatment was maintained.

Autres résumés

Type: plain-language-summary (eng)
Lay abstract PRECONNECT is an international study demonstrating the efficacy and tolerability of the drug combination trifluridine/tipiracil in adult patients with metastatic colorectal cancer treated in everyday clinical practice. For this publication, the authors conducted an analysis performed on the 161 Italian patients enrolled in this study. These kinds of analyses are important because of the differences that may arise across different countries. The most common contraindications were not dangerous to health. Furthermore, 3 months from beginning the medication, half of the patients did not show a worsening of the disease and quality of life during treatment was maintained.

Identifiants

pubmed: 33663264
doi: 10.2217/fon-2020-1278
doi:

Substances chimiques

Drug Combinations 0
Pyrrolidines 0
trifluridine tipiracil drug combination 0
Thymine QR26YLT7LT
Trifluridine RMW9V5RW38

Banques de données

ClinicalTrials.gov
['NCT03306394']

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

2315-2324

Subventions

Organisme : Servier, Italy

Auteurs

Alberto Zaniboni (A)

Fondazione Poliambulanza, Istituto Ospedaliero, Via Leonida Bissolati, 57, 25124, Brescia, Italy.

Carlo Antonio Barone (CA)

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Via della Pineta Sacchetti, 217, 00168, Roma, Italy.

Maria Chiara Banzi (MC)

AUSL-IRCCS S. Maria Nuova, Viale Risorgimento, 80, 42123, Reggio Emilia, Italy.

Francesca Bergamo (F)

Istituto Oncologico Veneto - IRCCS, Via Gattamelata, 64, 35128, Padova, Italy.

Livio Blasi (L)

Azienda Ospedaliera "Civico-Di Cristina-Benefratelli", Piazza Leotta Nicola, 4, 90127, Palermo, Italy.

Roberto Bordonaro (R)

Azienda Ospedaliera Garibaldi - Nesima, Via Palermo, 636, 95122, Catania, Italy.

Maria Di Bartolomeo (MD)

Fondazione IRCCS - Istituto Nazionale dei Tumori, Via Giacomo Venezian, 1, 20133, Milano, Italy.

Francesco Di Costanzo (FD)

Azienda Ospedaliero-Universitaria Careggi, Largo Piero Palagi, 1, 50139, Firenze, Italy.

Giovanni Luca Frassineti (GL)

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Via Piero Maroncelli, 40, 47014, Meldola (FC), Italy.

Carlo Garufi (C)

Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152, Roma, Italy.

Francesco Giuliani (F)

Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65, 70124, Bari, Italy.

Tiziana Pia Latiano (TP)

Ospedale IRCSS Casa Sollievo della Sofferenza, Viale Cappuccini, 1, 71013, San Giovanni Rotondo (FG), Italy.

Erika Martinelli (E)

Università degli Studi della Campania "Luigi Vanvitelli", Via Vico Luigi De Crecchio 6 - 80138, Napoli, Italy.

Nicola Personeni (N)

Medical Oncology & Hematology Unit, Humanitas Cancer Center, Humanitas Clinical and Research Center-IRCCS, Via Alessandro Manzoni, 56, 20089, Rozzano (Milan), Italy.
Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini, 20090, Pieve Emanuele (Milan), Italy.

Patrizia Racca (P)

A.O.U. Città della Salute e della Scienza di Torino, Corso Bramante, 88, 10126, Torino, Italy.

Emiliano Tamburini (E)

Ospedale Infermi, Via le Luigi Settembrini, 2, 47923, Rimini, Italy.

Giuseppe Tonini (G)

Policlinico Universitario Campus Biomedico, Via Álvaro del Portillo, 20000128, Roma, Italy.

Marie Georges Besse (MG)

Medical Affairs, Servier Italia, Via Luca Passi, 85, 00166, Roma, Italy.

Mario Spione (M)

Medical Affairs, Servier Italia, Via Luca Passi, 85, 00166, Roma, Italy.

Alfredo Falcone (A)

Dipartimento di Ricerca Traslazionale, Università degli Studi di Pisa, Lungarno Antonio Pacinotti, 43, 56126, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH